An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Tipifarnib (Primary)
- Indications Non-small cell lung cancer
- Focus Proof of concept; Therapeutic Use
- 05 Apr 2018 Status changed from planning to not yet recruiting.
- 16 Mar 2018 New trial record
- 12 Mar 2018 According to a Kura Oncology media release, this trial will be initiated through the Spanish Lung Cancer Group in 2018.